Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
RBLX enters its October 29 earnings with a fresh wave of analyst target upgrades, a stock up 8.7% on the week, and an options market turning measurably more cautious, a combination that sets up the print as the definitive near-term test.
The analyst story is the headline this week. JP Morgan and UBS both raised their targets to $53 on Wednesday, while DA Davidson moved to $50 from $40. All three kept Neutral ratings, meaning the Street is marking up its price cards without committing to the bull case. That follows Needham's Buy-rated raise to $55 last month and Wells Fargo's jump to $64. The consensus sits at Hold with a mean target of $49.88, almost exactly where the stock closed at $49.51 on Tuesday. The tight gap between price and consensus target reflects a divided community: bulls at Roth Capital ($60) and Wells Fargo ($64) argue the platform's 125 million daily active users and improving monetisation justify a premium, while Jefferies downgraded to Underperform with a $38 target in late September, citing execution risk around a young user base and super-voting governance. The EPS forward growth factor scores in the 88th percentile, pointing to meaningful estimate revision momentum over the past year, yet near-term EPS surprise and momentum scores sit in the mid-40s, suggesting the upgrade cycle has not yet fed through to near-term beat expectations.
Options positioning has turned more defensive than at any point in the past month. The put/call ratio has climbed to 0.70, roughly 1.7 standard deviations above its 20-day average of 0.62, and the trend is clear: PCR was running near 0.55 in mid-September and has drifted steadily higher through October. That is not panic, but it is the most cautious options setup RBLX has seen since early in the year. The 52-week high on the PCR is 0.91, so there is room to run further if anxiety about the October 29 date intensifies.
Short interest tells a more complicated story than the headline number suggests. Shares short have climbed 14% on the week to 27.7 million, putting SI at 4.2% of the free float, the highest level of recent weeks. But the borrow market is not tight. The cost to borrow has fallen 20% on the week to 0.44%, a low-cost tier reading. Availability is extraordinarily loose at nearly 5,900%, meaning there are roughly 410 million shares available to lend against a short base of 27 million. The short score sits at 35.7, well below the danger zone, and availability ranks in the 69th percentile for looseness. Bears are adding but are not paying up to do so, and there is zero squeeze pressure in the lending pool.
The earnings history is the sharpest fact in the data. Last quarter's print on July 30 produced a 29% single-day drop and a 28% decline over the following five days. That is not a pattern that encourages casual long positioning into a report, whatever the analyst upgrades say. The bull case from Benzinga cites management discussion pointing toward 140 to 145 million DAUs and bookings above $1.7 billion against guidance of $1.576 to $1.653 billion. The bear case points to fragmented discovery reducing hours per user and $1.808 billion bookings as a bar that still requires clean execution on user acquisition and monetisation efficiency. FMR LLC, the largest institutional holder, added 32.4 million shares in the most recent quarter to reach 10.9% of shares outstanding, which is the most significant ownership move in the data and represents a meaningful vote of confidence at the institutional level. All recent insider selling has been under pre-arranged 10b5-1 plans, so those transactions carry limited signal about management conviction.
Fifteen days to the October 29 print, the key variable is whether DAU and bookings guidance for Q4 suggests the July collapse was idiosyncratic or the start of a deceleration trend.
See the live data behind this article on ORTEX.
Open RBLX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.